LLS30

Research use only, not for human use.

LLS30 is a potent, allosteric Galectin-1 (Gal-1) inhibitor.

LLS30 is a potent, allosteric Galectin-1 (Gal-1) inhibitor, inhibits AR negative cells PC3, DU145, and AR positive cells, 22RV1 and CWR-R1 cells with IC50 of 10.4 μM, 5.3 μM, 3.3 μM and 5.9 μM, respectively; decreases Gal-1 binding affinity to its binding partners; showes in vivo efficacy in both AR positive and AR negative xenograft models; not only can potentiate the anti-tumor effect of docetaxel to cause complete regression of tumors, but also effectively inhibit the invasion and metastasis of PCa cells in vivo.

——

——

LLS-30

Cytoskeleton/Cell Adhesion Molecules

Galectin

Galectin

——

——

2138367-58-3

701.47

C34H33Cl4N5O3

>98% (HPLC)

——

O=C(N)CC(C1=CC=C2N(CC3=CC=C(Cl)C(Cl)=C3)C(C4=CC=C(N(CCO)CCO)C=C4)=NC2=C1)NCC5=CC=C(Cl)C(Cl)=C5

3-(2-(4-(bis(2-hydroxyethyl)amino)phenyl)-1-(3,4-dichlorobenzyl)-1H-benzo[d]imidazol-5-yl)-3-((3,4-dichlorobenzyl)amino)propanamide

(-20℃)

With Ice Pack

≥ 2 years